• AAPL 169.02
  • TSLA 162.13
  • AMZN 176.59
  • MSFT 409.06
  • INTC 34.5
  • EURUSD 1.07
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. GNLX.NASDAQ

Genelux Corporation Common Stock (GNLX NASDAQ) stock market data APIs

$3.5 0.05(1.4%) as of April 24, 2024

Genelux Corporation Common Stock Financial Data Overview

3.45
3.5
-
3.635
3.26
3.26-40.98
93 492 K
26 866 K
170 K
-0.25
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GNLX',
Type: 'Common Stock',
Name: 'Genelux Corporation Common Stock',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: '0001231457',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2023-01-26',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Genelux Corporation Common Stock Fundamental Data is available in our Financial Data APIs

  • Net Revenue 170 K
  • EBITDA -23 666 000
  • Earnings Per Share -1.16
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Genelux Corporation Common Stock Earnings via APIs

  • Latest Release 2024-03-29
  • EPS/Forecast -0.19

Get Genelux Corporation Common Stock End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Genelux Corporation Common Stock latest news via APIs

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance an...
  • BIOTECH
  • CANCER
  • GENELUX CORPORATION
  • GENELUX NEWS
  • NASDAQ:GNLX
  • ONCOLYTIC VIRUS NEWS
  • OVARIAN CANCER
  • OVARIAN CANCER NEWS
  • PRODUCT / SERVICES ANNOUNCEMENT

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalent...
  • BIOTECH
  • EARNINGS RELEASES AND OPERATING RESULTS
  • GENELUX CORPORATION
  • GENELUX NEWS
  • NASDAQ:GNLX
  • OLVI-VEC
Do you have any questions?
support@eodhistoricaldata.com